Please go to the PowerPak homepage
and select a course.
Total Patient Care in IBD: New Options for Treatment and Current Recommendations for Health Maintenance
Provided by Boston University School of Medicine and CE for pharmacists is provided by The University of Rhode Island College of Pharmacy.
This activity is supported by an independent educational grant from Pfizer Inc.
Estimated Time to Complete:
October 15, 2018
October 15, 2019
Utilizing an expert multidisciplinary faculty team and featuring video vignettes of ideal patient education encounters, this activity is designed to address several key issues. These issues include, but are not limited to: Gastroenterology (GI) clinicians may not be familiar with newer and emerging agents for the treatment of IBD in patients who are unable to achieve remission with other therapies; Patients with IBD are at increased risk for preventable disease and infection, yet they do not receive preventive services and vaccines at the same rate as the general population; Clinicians managing IBD patients may not have awareness of vaccine guidelines for patients with IBD.
Gastroenterologists, gastroenterology fellows, primary care physicians, NP/PAs, nurses, pharmacists and others who manage/treat patients with IBD
At the conclusion of this activity, participants will be able to:
- Discuss novel agents that are available and those in clinical trials for IBD in terms of therapeutic target, safety, and efficacy.
- Examine the risk of infection and various comorbidities in patients with IBD and the consequences of increased prevalence of these conditions.
- Discuss current rates for preventive services and vaccination in patients with IBD, barriers to these services, and strategies that the healthcare team can employ to overcome barriers.
- Explore current guideline recommendations for vaccination and health screening in patients with IBD focusing on updates and new vaccines.
Francis A. Farraye, MD, MSc
Clinical Director in the Section of Gastroenterology
Director of the Inflammatory Bowel Disease Center
Boston Medical Center
Professor of Medicine
Boston University School of Medicine
Beth-Ann Norton, MS, RN, ANP-BC
Nurse Practitioner and Nursing Program Director
Brigham and Women's Hospital Crohn's and Colitis Center
Chestnut Hill, MA
Toni Zahorian, PharmD, BCACP
Clinical Pharmacy Specialist – Ambulatory Care
Center for Digestive Disorders
Boston Medical Center
Accreditor Disclosure of Conflicts of Interest Policy:
The Boston University School of Medicine and University of Rhode Island College of Pharmacy ask all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME), Continuing Nursing Education (CNE) and Continuing Pharmacy Education (CPE), activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CE activity participants prior to the start of the educational activity. Boston University School of Medicine and University of Rhode Island have procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Dr. Farraye is a consultant for Braintree Laboratories, Janssen Biotech, Inc., Merck & Co. Inc., Pfizer Inc., and Takeda Pharmaceuticals, USA, Inc. He also is a stockholder and on the advisory board for Innovation Pharmaceuticals and is on the data safety management board for Eli Lilly and Company and Theravance Biopharma.
Ms. Beth-Ann Norton is a consultant for Takeda Pharmaceuticals, USA, Inc.
Ms. Toni Zahorian has no relevant financial relationships to disclose.
Michael Burk, Senior Program Manager, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.
Carmela Townsend, Lead Nurse Planner, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.
Dana Frazier, Program and Grant Manager, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.
Mary-Jane Kanaczet, M.Ed, Director of the Office of Continuing Professional Development College of Pharmacy, the University of Rhode Island, has no relevant financial relationships to disclose.
Bret Lashner, MD, Co-Course Director, Boston University School of Medicine Office of Continuing Medical Education and Professor of Medicine at the Cleveland Clinic, has no relevant financial relationships to disclose.
Beth-Ann Norton, a member of our faculty panel and CNE Course Advisor, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.
Laura Stinson, consultant medical editor, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
This is a knowledge-based educational activity. Pharmacists will receive 1.5 contact hour (0.15 ceus) for the home study program. No partial credit will be given. Release Date 10/15/18. Universal Activity Number (UAN): 0060-9999-18-036-H01-P.
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Disclosure of Unlabeled Use:
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
SPECIAL INSTRUCTIONS: Please note that all patients featured in the video vignettes are actors and not actual patients.
For questions about CME, please contact firstname.lastname@example.org or www.bu.edu/cme.
© Trustees of Boston University, 2018